Evolve104
Cervical Squamous Cell Carcinoma
EvolveImmune United, IncPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
16 Active assets in the Cervical Squamous Cell Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CIS-DIAMMINEDICHLOROPLATINUM II National Cancer Institute (NCI) | Phase 2 | BB |
FILGRASTIM National Cancer Institute (NCI) | Phase 2 | B |
PEGFILGRASTIM National Cancer Institute (NCI) | Phase 2 | B |
Veliparib National Cancer Institute (NCI) | Phase 2 | B |
Rigosertib Traws Pharma, Inc. | Phase 2 | B |
View all 32 →
Same molecule, other indications
Evolve104 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →